$CVRG Look Out This Week $ Converge Global, Inc. is

New Post Public Reply Private Reply Replies (0) Message Board
doobins

$CVRG Look Out This Week >>> $


CVRG Converge Global Inc. Candlestick Chart Penny Stock Picks

Converge Global, Inc. is a diverse company currently developing Majestic Menu, a division that will feature majesticmenu.com.

This online retail and commecial portal and media platform for gourmet connoisseurs and the hospitality and food service industries will assist in the identification and procurement of products and services from the local, national and international marketplace.

Majestic Menu is currently preparing for its retail test market and will feature current and progressive media and technological strategies. The portal will be a form of online purchasing that can be engaged to enhance or direct traditional retail and commercial distribution.

We've been watching CVRG for the last couple of weeks and there's a lot of buzz circulating about this stock. It is extremely thin, the L2 that is, and has a low NON-diluted 10 million share float. This means the stock is extremely volatile as you can see from the price action that took place on Friday.  A breeze can cause this stock to move up - substantially!

On Monday we should see this stock pop through the 200 MA and stay above it.  Majestic Menu launch, or test launch news, can break any day - when it does this stock is going through the roof. The news is imminent. It is our opinion that CVRG is going to see substantial volume and large gains this week. The stock is simply too thin and volatile for it to not.

Accumulation/distribution is completely maxed, as you can see on the chart. Everyone that's bought recently is holding - something is about to happen. The MACD turned up friday, the RSI is moving upwards due to increased buying, and the 200 MA is about to be broken.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Concerns Rise Over Trump's Cryptocurrency Reserve Strategy

Updated Category News Views 192

Concerns About Cryptocurrency Announcements Prominent economist and market commentator Peter Schiff has urged a Congressional investigation into President Donald Trump's recent foray into cryptocurrency, suggesting that these announcements may involve insider trading and market manipulation. The Key Questions Raised In a recent post on X, Schiff sought answers to several...

Continue Reading
BriaCell Joins Prestigious Program to Boost Cancer Treatments

Updated Category News Views 145

BriaCell Enters MSK’s 2025 Therapeutics Accelerator Program BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, TSX: BCT) is thrilled to share the news of its selection into the Memorial Sloan Kettering Cancer Center (MSK) Therapeutics Accelerator Program for 2025. This prestigious program is designed to fast-track the clinical development of many innovative cancer...

Continue Reading
Exploring Current Net Asset Values of WisdomTree Funds

Updated Category News Views 114

Understanding Net Asset Value (NAV) in Investment Funds Net Asset Value (NAV) is a crucial metric for evaluating the performance of investment funds, representing the value of a fund's assets minus its liabilities. It's important for investors to keep track of NAV as it aids in making informed decisions regarding their investments. Here, we delve into the recent NAVs of...

Continue Reading
DoorDash's Innovative Tools Transforming Restaurant Dynamics

Updated Category News Views 208

Introduction to DoorDash's Expansion DoorDash (NASDAQ: DASH) has recently unveiled exciting developments regarding its Commerce Platform. This significant enhancement is set to assist restaurants in boosting direct sales while fostering better customer relationships across multiple channels. New Features for Restaurant Success The introduced tools are designed to uplift...

Continue Reading
Mezzion's Udenafil Shows Promise in ADPKD Study

Updated Category News Views 34

Positive News for Udenafil in Kidney Disease New updates from Mezzion Pharma Co., Ltd. have come across quite promising. They've reported some favorable results in a preclinical study of udenafil, targeting autosomal dominant polycystic kidney disease (ADPKD). It appears that this PDE5 inhibitor, typically used in aiding cardiovascular issues, now shows potential in...

Continue Reading